Contact
searchSearch
HMP Global
Login

News

FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
Stephanie Holland
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
Allison Casey
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
News
Selinexor Improves PFS, Time to Next Treatment in Metastatic, Advanced Dedifferentiated Liposarcoma
06/02/2022
John Otrompke, BA, JD
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment...
06/02/2022
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
News
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors
10/26/2020
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS...
10/26/2020
Oncology
News
Doxorubicin–Pembrolizumab Combo Shows Promise in Advanced Anthracycline-Naïve Sarcoma
09/23/2020
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with...
09/23/2020
Oncology
News
Maintenance Cyclophosphamide Plus Celecoxib Feasible for Metastatic Ewing Sarcoma
05/31/2020
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen...
05/31/2020
Oncology
News
FDA Approves Pomalidomide for Certain Adults With Kaposi Sarcoma
05/15/2020
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved...
05/15/2020
Oncology
News
High Frequency of Pathogenic Germline Variants Observed in Patients With Osteosarcoma
05/06/2020
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be...
05/06/2020
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use